Previous 10 | Next 10 |
My plan for my investment in NantKwest ( NK ) was to build a conservative position in anticipation that the market will start to identify the prospective upside in the stock. Indeed, NantKwest still has a couple of years from a potential product launch. Still, I expect CEO and founder Dr. Soon...
First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting PD-L1 and CD16 in patients with solid tumors NantKwest establishes a leading portfolio of off-the-shelf NK cells at clinical stage of development with three e...
NantKwest ( Nasdaq:NK ) today announced the appointment of Cheryl L. Cohen to the Board of Directors of NantKwest, effective immediately. “Cheryl is a proven business executive and highly experienced board member in both the biotechnology and pharmaceutical sectors,” said...
5 out of 35 Durable Complete Responses Observed in Patients with Relapsed Third-Line Advanced Solid Tumors with Duration Ranging 4 to 24 Months Patrick Soon-Shiong, MD, Chairman and CEO of NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company ...
Phase Ib/II Clinical Trial Data Reported at 2019 Annual Meeting of the American Society of Clinical Oncology Shows High Overall Objective Response Rate (ORR) of 58% and Complete Response Rate (CR) of 33% in Relapsed/Refractory Lymphoma Patients NantKwest Inc. ( Nasdaq:NK ) announced t...
First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting CD16 and CD19 in patients with lymphoma NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing...
NantKwest ( Nasdaq:NK ), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong and Company management will be participating in the Jefferies 2019 Annual Healthcare Conference being held in New York City from June 4 th -7 th , 2...
Preclinical and Clinical Data Demonstrate Advanced Deployment of Precision Medicine Tools to Analyze and Potentially More Effectively Intervene with Highly Focused Therapeutic Interventions NantKwest ( Nasdaq:NK ), a leading clinical-stage, natural killer cell based therapeutics compa...
NK-92® Cell Based Bioanalytical Solutions are the Key to Optimizing R&D and Commercial Product Development Efforts for Monoclonal Antibodies, Bi-Specifics and Related Biological Products Brink Biologics, Inc. , a NantKwest, Inc. (Nasdaq:NK) affiliate who serves as e...
The enigmatic Dr. Patrick Soon-Shiong has created an interminable network of companies to take on just about every major issue in healthcare. Even with billions of dollars being invested into all his subdivided family of NantWorks, we don't know if all his endeavors are going to be successful....
News, Short Squeeze, Breakout and More Instantly...
NantKwest Company Name:
NK Stock Symbol:
NASDAQ Market:
Imerys Enters Long-Term Partnership with TotalEnergies for Renewable Power at its Santa Barbara County Facility PR Newswire A TotalEnergies solar and battery storage solution to bring 130-year-old Lompoc industrial site into new era of sustainability and smart energy manag...
Creates Leading Immunotherapy and Cell Therapy Company ImmunityBio , Inc. and NantKwest , Inc. ( NASDAQ: NK ), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing conditi...
NantKwest, Inc . ( NASDAQ: NK ), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote each of the proposals related to the pending merger of NantKwest and ImmunityBio, Inc. presented at the special ...